Is Legend Biotech Stock a Good Investment?
Legend Biotech Investment Advice | LEGN |
- Examine Legend Biotech's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Legend Biotech's leadership team and their track record. Good management can help Legend Biotech navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Legend Biotech's business and its evolving consumer preferences.
- Compare Legend Biotech's performance and market position to its competitors. Analyze how Legend Biotech is positioned in terms of product offerings, innovation, and market share.
- Check if Legend Biotech pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Legend Biotech's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Legend Biotech Corp stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Legend Biotech Corp is a good investment.
Sell | Buy |
Cautious Hold
Market Performance | Very Weak | Details | |
Volatility | Very steady | Details | |
Hype Condition | Low key | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Legend Biotech Stock
Researching Legend Biotech's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 56.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 1.92. Legend Biotech Corp had not issued any dividends in recent years.
To determine if Legend Biotech is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Legend Biotech's research are outlined below:
| Legend Biotech Corp generated a negative expected return over the last 90 days | |
| Legend Biotech Corp has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 285.14 M. Net Loss for the year was (518.25 M) with loss before overhead, payroll, taxes, and interest of (87.72 M). | |
| Legend Biotech Corp currently holds about 791.26 M in cash with (393.28 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.11. | |
| Roughly 56.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: Exane Asset Management Purchases Shares of 67,782 Legend Biotech Co. - MarketBeat |
Legend Biotech Quarterly Cost Of Revenue |
|
Legend Biotech uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Legend Biotech Corp. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Legend Biotech's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 4th of April 2024 Upcoming Quarterly Report | View | |
| 16th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Legend Biotech's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Legend Biotech's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2021-05-18 | 2021-03-31 | -0.35 | -0.3 | 0.05 | 14 | ||
2022-12-14 | 2022-09-30 | -0.31 | -0.37 | -0.06 | 19 | ||
2021-03-18 | 2020-12-31 | -0.28 | -0.22 | 0.06 | 21 | ||
2021-11-16 | 2021-09-30 | -0.35 | -0.43 | -0.08 | 22 | ||
2023-05-18 | 2023-03-31 | -0.78 | -0.68 | 0.1 | 12 | ||
2022-03-18 | 2021-12-31 | -0.41 | -0.3 | 0.11 | 26 | ||
2024-05-13 | 2024-03-31 | -0.34 | -0.16 | 0.18 | 52 | ||
2023-03-30 | 2022-12-31 | -0.44 | -0.62 | -0.18 | 40 |
Legend Biotech Target Price Consensus
Legend target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Legend Biotech's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 23 | Strong Buy |
Most Legend analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Legend stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Legend Biotech Corp, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationLegend Biotech Target Price Projection
Legend Biotech's current and average target prices are 36.42 and 79.83, respectively. The current price of Legend Biotech is the price at which Legend Biotech Corp is currently trading. On the other hand, Legend Biotech's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Legend Biotech Market Quote on 18th of February 2025
Target Price
Analyst Consensus On Legend Biotech Target Price
Legend Biotech Analyst Ratings
Legend Biotech's analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Legend Biotech stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Legend Biotech's financials, market performance, and future outlook by experienced professionals. Legend Biotech's historical ratings below, therefore, can serve as a valuable tool for investors.Know Legend Biotech's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Legend Biotech is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Legend Biotech Corp backward and forwards among themselves. Legend Biotech's institutional investor refers to the entity that pools money to purchase Legend Biotech's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Capital Research & Mgmt Co - Division 3 | 2024-12-31 | 2.2 M | Wellington Management Company Llp | 2024-12-31 | 2.1 M | Federated Hermes Inc | 2024-09-30 | 1.5 M | Artisan Partners Limited Partnership | 2024-12-31 | 1.5 M | Citadel Advisors Llc | 2024-09-30 | 1.3 M | Alliancebernstein L.p. | 2024-09-30 | 1.3 M | Matthews International Cap Mgmt Llc | 2024-12-31 | 1.2 M | State Street Corp | 2024-09-30 | 1.1 M | Arrowmark Colorado Holdings, Llc (arrowmark Partners) | 2024-09-30 | 953.6 K | Fmr Inc | 2024-09-30 | 18.3 M | T. Rowe Price Associates, Inc. | 2024-09-30 | 11.2 M |
Legend Biotech's market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 6.68 B.Market Cap |
|
Legend Biotech's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.32) | (0.34) | |
| Return On Capital Employed | (0.31) | (0.33) | |
| Return On Assets | (0.32) | (0.34) | |
| Return On Equity | (0.48) | (0.45) |
Determining Legend Biotech's profitability involves analyzing its financial statements and using various financial metrics to determine if Legend Biotech is a good buy. For example, gross profit margin measures Legend Biotech's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Legend Biotech's profitability and make more informed investment decisions.
Evaluate Legend Biotech's management efficiency
Legend Biotech Corp has return on total asset (ROA) of (0.1228) % which means that it has lost $0.1228 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2835) %, meaning that it created substantial loss on money invested by shareholders. Legend Biotech's management efficiency ratios could be used to measure how well Legend Biotech manages its routine affairs as well as how well it operates its assets and liabilities. As of the 18th of February 2025, Return On Tangible Assets is likely to drop to -0.34. In addition to that, Return On Capital Employed is likely to drop to -0.33. At this time, Legend Biotech's Intangibles To Total Assets are very stable compared to the past year. As of the 18th of February 2025, Debt To Assets is likely to grow to 0.17, while Other Assets are likely to drop 1.09.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 6.40 | 6.72 | |
| Tangible Book Value Per Share | 6.38 | 6.69 | |
| Enterprise Value Over EBITDA | (23.21) | (22.05) | |
| Price Book Value Ratio | 9.74 | 9.25 | |
| Enterprise Value Multiple | (23.21) | (22.05) | |
| Price Fair Value | 9.74 | 9.25 | |
| Enterprise Value | 8.7 B | 5.2 B |
At Legend Biotech Corp, effective management practices are pivotal to sustaining long-term profitability. We delve into financial metrics and market conditions to provide a comprehensive analysis of the stock's prospects.
Beta 0.177 |
Basic technical analysis of Legend Stock
As of the 18th of February 2025, Legend Biotech secures the Standard Deviation of 3.05, mean deviation of 2.28, and Risk Adjusted Performance of (0.01). In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Legend Biotech Corp, as well as the relationship between them.Legend Biotech's Outstanding Corporate Bonds
Legend Biotech issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Legend Biotech Corp uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Legend bonds can be classified according to their maturity, which is the date when Legend Biotech Corp has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| LEGG MASON INC Corp BondUS524901AV77 | View | |
| LEGG MASON INC Corp BondUS524901AR65 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View |
Understand Legend Biotech's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Legend Biotech's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.01) | |||
| Market Risk Adjusted Performance | (0.20) | |||
| Mean Deviation | 2.28 | |||
| Coefficient Of Variation | (3,131) | |||
| Standard Deviation | 3.05 | |||
| Variance | 9.29 | |||
| Information Ratio | (0.04) | |||
| Jensen Alpha | (0.11) | |||
| Total Risk Alpha | (0.11) | |||
| Treynor Ratio | (0.21) | |||
| Maximum Drawdown | 13.49 | |||
| Value At Risk | (4.40) | |||
| Potential Upside | 5.06 | |||
| Skewness | 0.1349 | |||
| Kurtosis | 0.7803 |
| Risk Adjusted Performance | (0.01) | |||
| Market Risk Adjusted Performance | (0.20) | |||
| Mean Deviation | 2.28 | |||
| Coefficient Of Variation | (3,131) | |||
| Standard Deviation | 3.05 | |||
| Variance | 9.29 | |||
| Information Ratio | (0.04) | |||
| Jensen Alpha | (0.11) | |||
| Total Risk Alpha | (0.11) | |||
| Treynor Ratio | (0.21) | |||
| Maximum Drawdown | 13.49 | |||
| Value At Risk | (4.40) | |||
| Potential Upside | 5.06 | |||
| Skewness | 0.1349 | |||
| Kurtosis | 0.7803 |
Consider Legend Biotech's intraday indicators
Legend Biotech intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Legend Biotech stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Legend Biotech Corporate Filings
| 14th of February 2025 Other Reports | ViewVerify | |
6K | 22nd of January 2025 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
| 14th of November 2024 Other Reports | ViewVerify |
Legend Stock media impact
Far too much social signal, news, headlines, and media speculation about Legend Biotech that are available to investors today. That information is available publicly through Legend media outlets and privately through word of mouth or via Legend internal channels. However, regardless of the origin, that massive amount of Legend data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Legend Biotech news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Legend Biotech relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Legend Biotech's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Legend Biotech alpha.
Legend Biotech Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Legend Biotech can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Top Midday Decliners
recently @ finance.yahoo.com
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Legend Biotech Corp Historical Investor Sentiment
Investor biases related to Legend Biotech's public news can be used to forecast risks associated with an investment in Legend. The trend in average sentiment can be used to explain how an investor holding Legend can time the market purely based on public headlines and social activities around Legend Biotech Corp. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Legend Biotech's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Legend Biotech and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Legend Biotech news discussions. The higher the estimate score, the more favorable the investor's outlook on Legend Biotech.
Legend Biotech Maximum Pain Price Across May 16th 2025 Option Contracts
Legend Biotech's options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Legend Biotech close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Legend Biotech's options.
Legend Biotech Corporate Management
| Elaine Qian | VP Resources | Profile | |
| James JD | General Counsel | Profile | |
| Lori CPA | Chief Officer | Profile | |
| Tina Carter | Corporate Lead | Profile | |
| Steven Gavel | US Development | Profile | |
| Marc Harrison | VP Counsel | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Legend Biotech Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Legend Biotech. If investors know Legend will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Legend Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.92) | Revenue Per Share | Quarterly Revenue Growth 0.669 | Return On Assets | Return On Equity |
The market value of Legend Biotech Corp is measured differently than its book value, which is the value of Legend that is recorded on the company's balance sheet. Investors also form their own opinion of Legend Biotech's value that differs from its market value or its book value, called intrinsic value, which is Legend Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Legend Biotech's market value can be influenced by many factors that don't directly affect Legend Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Legend Biotech's value and its price, as these two are different measures arrived at by various means. Investors typically determine if Legend Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Legend Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.